Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL)
Stéphanie Gaillard, Ana Oaknin, Isabelle Ray‐Coquard, Ignace Vergote, Giovanni Scambia, Nicoletta Colombo, Cristian Fernández, Vicente Alfaro, Carmen Kahatt, Antonio Nieto, Ali Zeaiter, Miguel Aracil, Laura Vidal, Beatriz Pardo-Burdalo, Zsuzsanna Pápai, Rebecca Kristeleit, David M. O’Malley, Ivor Benjamin, Patricia Pautier, Domenica Lorusso
Topics & Concepts
MedicineTopotecanClinical endpointInternal medicineRandomized controlled trialOvarian cancerNauseaPhases of clinical researchAdverse effectNeutropeniaChemotherapySurgeryGastroenterologyOncologyCancerOvarian cancer diagnosis and treatmentNanoparticle-Based Drug DeliveryIntraperitoneal and Appendiceal Malignancies